Analytical Verification of Cell-free DNA Next-generation Sequencing Assay for NSCLC at Princess Margaret Cancer Centre

Share Article

Dr. Tracy Stockley will present her findings in a LabRoots webinar June 28, 2017, on analytical verification of cell-free DNA next-generation sequencing assay for NSCLC.

Tracy Stockley PhD, FCCMG, FACMG Associate Professor, Princess Margaret Cancer Centre

The Advanced Molecular Diagnostic Laboratory at the Princess Margaret Cancer Centre in Toronto, Canada completed analytical verification of the Oncomine Lung cfDNA Assay. The next-generation sequencing (NGS) assay from Thermo Fisher Scientific enables the AMDL to detect mutations in cell-free DNA from non-small cell lung cancer samples.

Over the last 10 months, Dr. Tracy Stockley, associate professor at the Princess Margaret Cancer Centre, led testing of 60 samples using both NGS and droplet digital PCR (ddPCR). Evaluating detection of the T790M mutation in EGFR, a commonly implicated mutation in NSCLC, Stockley and her team achieved 100% confirmation at 0.1% limit of detection or above.

“We are encouraged by the results of the verification study,” Stockley says. “Our ability to confirm T790M mutations with NGS is important because of the added benefits of an NGS assay. With the Oncomine cfDNA assay, we detected additional variants including Exon 19 deletions and mutations in Exon 21 L858R,” she added.

Stockley will present her findings in a LabRoots webinar June 28, 2017, at 10:30 am PDT, 1:30 pm EDT. To learn more about this event, discover the continuing education credits offered, or to register for free, click here.

Dr. Stockley is a clinical molecular geneticist and associate director of the Molecular Diagnostics Division at the University Health Network, providing leadership within the two-divisional molecular diagnostic laboratories. Her research interests include the development of novel molecular diagnostic testing using high-throughput methodologies, and implementation and evaluation of genetic and genomic tests, particularly for acquired and inherited cancers.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website